⌕
Aurinia Pharmaceuticals · AUPH · Nasdaq
Tenet 82 · Strong
Compare
$15.40−0.52%At closeTenet 82 · Strong
$15.40−0.08 (−0.52%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Aurinia Pharmaceuticals (AUPH) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AUPH's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchOct 30, 2026 · 10:05 ETEARNINGS EXPECTED BY FEB 11
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.23 per share a year ago.…

AUPH −0.5% todayRead at source ↗
● Business WireOct 30, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 11
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress.…

AUPH −0.5% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 11
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

AUPH −0.5% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 10:46 ET
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.…

AUPH −0.5% todayRead at source ↗
● Zacks Investment ResearchOct 23, 2026 · 10:50 ET
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.…

AUPH −0.5% todayRead at source ↗
● Defense WorldOct 12, 2026 · 02:15 ETEARNINGS EXPECTED BY FEB 11
Critical Review: Aurinia Pharmaceuticals (NASDAQ:AUPH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL)

Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two business…

AUPH −0.5% todayRead at source ↗
● Zacks Investment ResearchAug 20, 2026 · 13:25 ET
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.…

AUPH −0.5% todayRead at source ↗
● BenzingaAug 20, 2026 · 09:30 ET
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).…

AUPH −0.5% todayRead at source ↗
● Business WireAug 19, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.…

AUPH −0.5% todayRead at source ↗
Business Wire · Aug 19, 2026

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 11. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just AUPH · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.